EGFR and neoplasm: NK cells, can be primed and modified ex vivo, in a similar manner to CAR-T cells (231), to express a CD38-CD3ξ domain required for NK cell signaling and scFv antibody fragments to introduce specificity to a range of diverse tumor antigens, including those targeting the cell-surface EGFR or/and EGFRvIII.